Erenumab is a medicine being tested to see if it can help prevent episodic migraines (headaches that happen occasionally) in kids aged 6-17. This study lasts up to 79 weeks, and involves several phases with different treatments and follow-ups. In the beginning, participants will be randomly assigned to get either erenumab (in different doses based on weight) or a placebo (a fake medicine) for 12 to 24 weeks. After that, everyone has a chance to receive erenumab for another 40 weeks. The study will also check how safe it is. To join, kids must have had migraines for at least a year, with 4-14 migraine days a month. They cannot have other severe headaches or been unresponsive to two or more migraine prevention medications.
- This study is long, lasting up to 79 weeks.
- Participants might receive different doses of erenumab or a placebo.
- Participants need to have frequent migraines but cannot have other serious health issues.
How understandable was the trial content above?
Hard to understand
Easy to understand